2. Academic Validation
  3. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease

  • Int J Mol Sci. 2021 Apr 21;22(9):4344. doi: 10.3390/ijms22094344.
Helena Iznardo 1,  Lluís Puig 1 2
Affiliations

Affiliations

  • 1 Dermatology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • 2 Department of Medicine, School of Medicine, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
PMID: 33919434 DOI: 10.3390/ijms22094344
Abstract

Unmet needs in the treatment of psoriasis call for novel therapeutic strategies. Pustular psoriasis and psoriatic arthritis often represent a therapeutic challenge. Focus on IL-36 cytokines offers an interesting approach, as the IL-36 axis has been appointed a critical driver of the autoinflammatory responses involved in pustular psoriasis. Two IL-36R blocking Antibodies, imsidolimab and spesolimab, are currently undergoing phase II and III clinical trials, with promising results.

Keywords

IL-36; IL-36R; imsidolimab; pathogenesis; psoriasis; psoriatic arthritis; pustular psoriasis; spesolimab.

Figures
Products